PHASE-I TRIAL OF N-(PHOSPHONACETYL)-L-ASPARTIC ACID (PALA)
- 1 January 1980
- journal article
- research article
- Vol. 64 (10-1), 1067-1071
Abstract
N-(Phosphonacetyl)-L-aspartic acid (PALA) was given as a 5 day continuous infusion in a phase I trial. Dose-limiting toxic effects noted were diarrhea occurring at doses of .gtoreq. 6 g/m2 per course, mucositis occurring at doses of .gtoreq. 7.5 g/m2 per course and skin rash occurring at doses > 9 g/m2 per course. No significant CNS, hemorrhagic, gastrointestinal or hematologic toxicity was noted. In patients with measurable tumor volume, no significant antitumor responses were seen. A dose of 9 g/m2 per course is recommended for a phase II trial.This publication has 2 references indexed in Scilit:
- EFFECTS OF N-(PHOSPHONACETYL)-L-ASPARTATE ON MURINE TUMORS AND NORMAL TISSUES INVIVO AND INVITRO AND RELATIONSHIP OF SENSITIVITY TO RATE OF PROLIFERATION AND LEVEL OF ASPARTATE-TRANSCARBAMYLASE1978
- Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-aspartate in vivoBiochemical Pharmacology, 1977